MCID: FTT008
MIFTS: 31

Fatty Liver Disease, Nonalcoholic 1

Categories: Liver diseases

Aliases & Classifications for Fatty Liver Disease, Nonalcoholic 1

MalaCards integrated aliases for Fatty Liver Disease, Nonalcoholic 1:

Name: Fatty Liver Disease, Nonalcoholic 1 54 29
Hepatic Steatosis 71 29
Fatty Liver Disease, Nonalcoholic, Susceptibility to, 1 13
Non-Alcoholic Fatty Liver Disease 1 71
Steatohepatitis 69
Fatty Liver 69
Nafld1 71

Characteristics:

OMIM:

54
Miscellaneous:
genetic heterogeneity

Inheritance:
multifactorial


HPO:

32
fatty liver disease, nonalcoholic 1:
Inheritance heterogeneous


Classifications:



External Ids:

OMIM 54 613282
MeSH 42 D005234
SNOMED-CT via HPO 65 197321007 442191002

Summaries for Fatty Liver Disease, Nonalcoholic 1

OMIM : 54
The accumulation of excess triglyceride in the liver, a condition known as hepatic steatosis (or fatty liver), is associated with adverse metabolic consequences including insulin resistance and dyslipidemia. Factors promoting deposition of fat in the liver include obesity, diabetes, insulin resistance, and alcohol ingestion. Nonalcoholic fatty liver disease (NAFLD) is the most common form of liver disease in Western countries. In a subset of individuals hepatic steatosis promotes an inflammatory response in the liver, referred to as steatohepatitis, which can progress to cirrhosis and liver cancer (summary by Romeo et al., 2008). Cohen et al. (2011) reviewed nonalcoholic fatty liver disease. (613282)

MalaCards based summary : Fatty Liver Disease, Nonalcoholic 1, also known as hepatic steatosis, is related to lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules and hypobetalipoproteinemia, and has symptoms including hepatic steatosis An important gene associated with Fatty Liver Disease, Nonalcoholic 1 is NAFLD1 (Fatty Liver Disease 1, Susceptiblity To). The drugs Amlodipine and Perindopril have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and bone.

UniProtKB/Swiss-Prot : 71 Non-alcoholic fatty liver disease 1: A condition characterized by accumulation of triglycerides in the liver. It is associated with adverse metabolic consequences, including insulin resistance and dyslipidemia. In a subset of individuals, hepatic steatosis promotes an inflammatory response in the liver, referred to as steatohepatitis, which can progress to cirrhosis and liver cancer. NAFLD is the most common form of liver disease in Western countries.

Related Diseases for Fatty Liver Disease, Nonalcoholic 1

Diseases in the Fatty Liver Disease, Nonalcoholic 1 family:

Fatty Liver Disease, Nonalcoholic 2

Diseases related to Fatty Liver Disease, Nonalcoholic 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 74)
id Related Disease Score Top Affiliating Genes
1 lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules 12.0
2 hypobetalipoproteinemia 11.3
3 nonalcoholic steatohepatitis 11.2
4 lipodystrophy, congenital generalized, type 3 11.0
5 lipodystrophy, congenital generalized, type 2 11.0
6 lipodystrophy, familial partial, type 2 11.0
7 visceral steatosis 11.0
8 abetalipoproteinemia 10.9
9 adrenomyodystrophy 10.9
10 chylomicron retention disease 10.9
11 citrullinemia, adult-onset type ii 10.9
12 lipodystrophy, congenital generalized, type 1 10.9
13 combined oxidative phosphorylation deficiency 21 10.9
14 neutral lipid storage disease with myopathy 10.9
15 combined oxidative phosphorylation deficiency 16 10.9
16 lipodystrophy, congenital generalized, type 4 10.9
17 lipodystrophy, familial partial, type 6 10.9
18 lipodystrophy, familial partial, type 5 10.9
19 trifunctional protein deficiency 10.9
20 3-methylglutaconic aciduria, type v 10.9
21 hepatitis 10.8
22 obesity 10.4
23 hepatitis c 10.4
24 fatty liver disease 10.1
25 liver disease 10.1
26 glucose intolerance 10.1
27 hypertriglyceridemia 10.1
28 hepatitis b 10.0
29 hepatitis c virus 10.0
30 lipodystrophy 10.0
31 insulinoma 9.9
32 polycystic ovary syndrome 9.9
33 alcoholic hepatitis 9.9
34 pancreatitis 9.8
35 psoriatic arthritis 9.8
36 arthritis 9.8
37 influenza 9.8
38 cholestasis 9.8
39 hyperhomocysteinemia 9.8
40 intrahepatic cholestasis 9.8
41 viral hepatitis 9.8
42 hepatocellular carcinoma 9.8
43 metastatic insulinoma 9.8
44 lactic acidosis 9.8
45 hyperglycemia 9.8
46 hemochromatosis 9.8
47 microsporidiosis 9.8
48 glucocorticoid resistance 9.6
49 alcohol abuse 9.6
50 portal hypertension 9.6

Graphical network of the top 20 diseases related to Fatty Liver Disease, Nonalcoholic 1:



Diseases related to Fatty Liver Disease, Nonalcoholic 1

Symptoms & Phenotypes for Fatty Liver Disease, Nonalcoholic 1

Symptoms via clinical synopsis from OMIM:

54

Abdomen- Liver:
fatty liver (hepatic steatosis), nonalcoholic


Clinical features from OMIM:

613282

Human phenotypes related to Fatty Liver Disease, Nonalcoholic 1:

32
id Description HPO Frequency HPO Source Accession
1 hepatic steatosis 32 HP:0001397

Drugs & Therapeutics for Fatty Liver Disease, Nonalcoholic 1

Drugs for Fatty Liver Disease, Nonalcoholic 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 245)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amlodipine Approved Phase 4 88150-42-9 2162
2
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
3
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
4
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
5
Zinc Approved Phase 4,Phase 2 7440-66-6 32051 23994
6
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 111025-46-8 4829
7
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
8
Insulin Aspart Approved Phase 4 116094-23-6 16132418
9
Insulin Detemir Approved Phase 4 169148-63-4 5311023
10
Selenium Approved, Vet_approved Phase 4 7782-49-2
11
Gliclazide Approved Phase 4 21187-98-4 3475
12
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2 44147092
13
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173
14
Insulin Glargine Approved Phase 4 160337-95-1
15
Ethanol Approved Phase 4,Phase 3 64-17-5 702
16
Glimepiride Approved Phase 4 93479-97-1 3476
17 Tocopherol Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2
18
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 59-02-9 14985
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
20
Pyridoxal Approved, Nutraceutical Phase 4,Phase 3 66-72-8 1050
21
Pyridoxine Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 65-23-6 1054
22
Angiotensin II Investigational Phase 4,Phase 3,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
23 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 3,Phase 2
24 Angiotensin Receptor Antagonists Phase 4,Phase 3,Phase 2
25 Angiotensin-Converting Enzyme Inhibitors Phase 4
26 Angiotensinogen Phase 4,Phase 3,Phase 2
27 Antihypertensive Agents Phase 4,Phase 3,Phase 2
28 calcium channel blockers Phase 4
29 Calcium, Dietary Phase 4,Phase 2
30 HIV Protease Inhibitors Phase 4,Phase 2,Phase 1
31 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32
protease inhibitors Phase 4,Phase 2,Phase 1
33 Vasodilator Agents Phase 4,Phase 2,Phase 3
34 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1
35 insulin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Micronutrients Phase 4,Phase 3,Phase 2
38 Tocopherols Phase 4,Phase 3,Phase 1,Phase 2
39 Tocotrienols Phase 4,Phase 3,Phase 1,Phase 2
40 Trace Elements Phase 4,Phase 3,Phase 2
41 Vitamins Phase 4,Phase 3,Phase 1,Phase 2
42 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
43 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
45 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
47 Incretins Phase 4,Phase 2,Phase 3
48 Antioxidants Phase 4,Phase 3,Phase 2,Phase 1
49 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Glucagon-Like Peptide 1 Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 235)

id Name Status NCT ID Phase Drugs
1 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
2 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
3 Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Completed NCT01006889 Phase 4 Exenatide
4 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
5 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
6 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
7 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
8 Antidiabetic Effects on Intrahepatic Fat Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
9 Pioglitazone in Hepatitis C Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
10 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
11 Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects Recruiting NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
12 Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes Recruiting NCT02303730 Phase 4 Exenatide;insulin glargine
13 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Recruiting NCT02051842 Phase 4 Metadoxine
14 SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD Recruiting NCT02649465 Phase 4 Tofogliflozin;Glimepiride
15 Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Recruiting NCT02500147 Phase 4 Metformin;Placebo
16 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Recruiting NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
17 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease Enrolling by invitation NCT03222206 Phase 4 Salsalate
18 Silymarin in NAFLD Not yet recruiting NCT02973295 Phase 4 Silymarin
19 Rifaximin in Fatty Liver Disease Terminated NCT01355575 Phase 4 Rifaximin
20 Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease Withdrawn NCT01269320 Phase 4 Femarelle
21 Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores Unknown status NCT00658164 Phase 3
22 Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01623024 Phase 3 Vitamin D
23 A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease Unknown status NCT02265276 Phase 3 Saroglitazar;Pioglitazone
24 Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis Completed NCT02068339 Phase 3 Oltipraz 1 (90mg);Placebo;Oltipraz 2 (120mg)
25 Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) Completed NCT00063635 Phase 3 Metformin;Matching placebo
26 Efficacy of Oral Trigonella Foenum-graecum Seed Extract Vs Placebo in Treatment of None Alcoholic Fatty Liver Disease Completed NCT02303314 Phase 2, Phase 3 Trigonella Foenum-graecum Seed Extract;Drug: Placebo
27 The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Completed NCT02030977 Phase 2, Phase 3
28 Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS) Completed NCT00063622 Phase 3 Pioglitazone;Matching placebo
29 Role of Exenatide in NASH-a Pilot Study Completed NCT00650546 Phase 2, Phase 3 Exenatide
30 Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH Completed NCT00267670 Phase 2, Phase 3 Pentoxifylline;Placebo
31 Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes Completed NCT02132442 Phase 3
32 The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Completed NCT01791959 Phase 2, Phase 3
33 Anti-Fibrotic Effects of Losartan In Nash Evaluation Study Completed NCT01051219 Phase 3 Losartan
34 Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis Recruiting NCT02541045 Phase 3 metadoxine
35 Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults Recruiting NCT02654665 Phase 3 Liraglutide
36 Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment Recruiting NCT02548351 Phase 3 Obeticholic Acid;Placebo
37 Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) Recruiting NCT02704403 Phase 3 Elafibranor;Placebo
38 Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Recruiting NCT03053063 Phase 3 SEL;Placebo
39 Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis Recruiting NCT03053050 Phase 3 SEL;Placebo
40 AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH Recruiting NCT03028740 Phase 3 Cenicriviroc;Placebo
41 Curcumin Supplement in Nonalcoholic Fatty Liver Patients With Type 2 Diabetes Not yet recruiting NCT02908152 Phase 2, Phase 3
42 The Effects of Coffee Main Constituents (Caffeine and Chlorogenic Acid) Supplementation on Inflammatory, Metabolic Factors, Hepatic Steatosis and Fibrosis in None- Alcoholic Fatty Liver Patients With Type 2 Diabetes Not yet recruiting NCT02929901 Phase 2, Phase 3
43 Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis Withdrawn NCT01384578 Phase 3 pentoxiphylline and Vitamin E;Vitamin E
44 Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH) Unknown status NCT00699036 Phase 2 avandia;metformin;losartan
45 Potential Role of n-3 Fatty Acids in the Treatment of NAFLD in Pediatric Patients Unknown status NCT02201160 Phase 1, Phase 2
46 Efficacy and Safety of Oltipraz in the Patients With Non-alcoholic Fatty Liver Disease Completed NCT01373554 Phase 2 Placebo;Oltipraz
47 The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease Completed NCT02546609 Phase 2 Sildenafil 1.0 mg;Metformin;Leucine;Placebo;Sildenafil Citrate 0.5 mg
48 The Effect of n-3 Polyunsaturated Fatty Acid Supplements in Patients With Non-alcoholic Fatty Liver Disease Completed NCT00819338 Phase 2
49 Effect of Treatment With Insulin Sensitizer on Arterial Properties, Metabolic Parameters and Liver Function in Patients With Nonalcoholic Fatty Liver Disease Completed NCT01084486 Phase 1, Phase 2 Metformin
50 Iron Depletion Therapy for Type 2 DM and NAFLD Completed NCT00230087 Phase 2

Search NIH Clinical Center for Fatty Liver Disease, Nonalcoholic 1

Genetic Tests for Fatty Liver Disease, Nonalcoholic 1

Genetic tests related to Fatty Liver Disease, Nonalcoholic 1:

id Genetic test Affiliating Genes
1 Fatty Liver Disease, Nonalcoholic 1 29
2 Hepatic Steatosis 29

Anatomical Context for Fatty Liver Disease, Nonalcoholic 1

MalaCards organs/tissues related to Fatty Liver Disease, Nonalcoholic 1:

39
Liver, Testes, Bone, Endothelial, Ovary

Publications for Fatty Liver Disease, Nonalcoholic 1

Variations for Fatty Liver Disease, Nonalcoholic 1

Expression for Fatty Liver Disease, Nonalcoholic 1

Search GEO for disease gene expression data for Fatty Liver Disease, Nonalcoholic 1.

Pathways for Fatty Liver Disease, Nonalcoholic 1

GO Terms for Fatty Liver Disease, Nonalcoholic 1

Sources for Fatty Liver Disease, Nonalcoholic 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....